Purple Biotech (PPBT) announced new data on its CAPTN-3 tri-specific antibody IM1240 generated in the laboratory of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Using fresh biopsies of HNSCC patients who have acquired resistance to anti-PD1 therapy, Dr. Horowitz’s results have shown induction of cancer cell apoptosis by the tri-specific IM1240, while none of the related variant bispecifics, having either a non-functional CD3 arm or NKG2A arm, showed an effect. The results correlate with patient-derived NSCLC tumor explants previously reported and suggest a synergistic effect of the CD3 and the NKG2A arms, a design which is unique to Purple’s CAPTN-3 platform.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PPBT:
- Purple Biotech Expands CAPTN-3 Portfolio with Novel Antibody Targeting TROP2
- Purple Biotech expands CAPTN-3 portfolio with IM1305
- Purple Biotech files to sell 2.7M American Depositary Shares, warrants
- Purple Biotech Reports Q2 2025 Financial Results and Clinical Progress
- Purple Biotech reports Q2 EPS 40c vs $1.80 last year